This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Hoffmann-La Roche Inc., Ludwig-Maximilians-Universitat München, Other. Active years: 2020-2023.
Company Filing History:
1 out of 5,020 
1 out of 50 
1 out of 834,411 Years Active: 2020-2023
Title: Raffaella Castoldi: Innovator in Bispecific Antibody Molecules
Introduction
Raffaella Castoldi is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of medicine through her innovative work on bispecific antibody molecules. With a total of two patents to her name, her research focuses on enhancing the efficacy of cancer treatments.
Latest Patents
Raffaella's latest patents include groundbreaking developments in bispecific antibody molecules that interact with antigen-transfected T-cells. These molecules feature a first binding domain that targets an antigen on CD8+ T-cells, which does not naturally occur on these cells. The second binding domain is designed to bind to a tumor-specific antigen found on the surface of tumor cells. This innovative approach allows for the combination of bispecific antibody molecules with transduced CD8+ T-cells, which can significantly improve treatment regimens for specific diseases.
Career Highlights
Throughout her career, Raffaella has worked with notable organizations, including Hoffmann-La Roche Inc. and Ludwig Maximilians University of Munich. Her experience in these institutions has allowed her to develop her expertise in antibody research and therapeutic applications.
Collaborations
Raffaella has collaborated with esteemed colleagues in her field, including Carole Bourquin and Stefan Endres. These partnerships have further enriched her research and contributed to the advancement of medical treatments.
Conclusion
Raffaella Castoldi's innovative work in bispecific antibody molecules represents a significant advancement in medical science. Her contributions are paving the way for more effective cancer therapies and improving patient outcomes.